TABLE 1.

Study design

GroupnVaccine administered at the following mo of the study:
Time zero13
17Ad35.CSAd35.CS
27RTS,S/AS01BRTS,S/AS01BRTS,S/AS01B
37RTS,S/AS01BRTS,S/AS01BAd35.CS
47Ad35.CSRTS,S/AS01BRTS,S/AS01B
54Ad35 emptyAd35 empty